Previous 10 | Next 10 |
CARLSBAD, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designatio...
CARLSBAD, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designatio...
Qualigen Therapeutics ( NASDAQ: QLGN ) has received Nasdaq notice, informing the company that it has regained compliance minimum bid price requirement and the matter is now closed. The closing bid price of the company’s common stock having been at least $1.00 per share for ...
CARLSBAD, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designatio...
CARLSBAD, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designatio...
Action to comply with continued listing requirements for Nasdaq Capital Market CARLSBAD, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN Qualigen Therapeutics, Inc.), a diversified life sciences company focused on developing treatments for adu...
Qualigen Therapeutics press release ( NASDAQ: QLGN ): Q3 GAAP EPS of -$0.10 beats by $0.06 . Revenue of $1.44M (+24.1% Y/Y) misses by $0.18M . For further details see: Qualigen Therapeutics GAAP EPS of -$0.10 beats by $0.06, revenue of $1.44M misses by $0...
Q3 2022 FastPack ® sales increased approximately 25% year-over-year Company continues to execute on and advance core therapeutic programs CARLSBAD, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN Qualigen Therapeutic...
Fou r th RAS Initiative Symposium Highlights Preclinical Data in Solid Tumor Models CARLSBAD, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing t...
CARLSBAD, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today anno...
News, Short Squeeze, Breakout and More Instantly...
Qualigen Therapeutics Inc. Company Name:
QLGN Stock Symbol:
NASDAQ Market:
Qualigen Therapeutics Inc. Website:
CHASKA, Minn., July 01, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced it has reached a cooperation agreemen...
A look at the top 10 most actives in the United States NLS Pharmaceutics Ltd. (NLSP) rose 156.2% to $0.38 on volume of 125,047,059 shares Reliance Global Group Inc. (RELI) rose 210.8% to $0.69 on volume of 110,427,102 shares Mustang Bio Inc. (MBIO) rose 53.3% to $1.15 on volume of 87,727,...
BowFlex Inc. (BFXXQ) is expected to report for Q4 2024 Leafbuyer Technologies Inc (LBUY) is expected to report for Q3 2024 Pacific Booker Minerals Inc (PBMLF) is expected to report for Q1 2025 BZAM Ltd Com (BZAMF) is expected to report for Q1 2024 MJ Holdings Inc (MJNE) is expecte...